NASDAQ$MMSI

Merit Medical Systems Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Merit Medical's Q3 2024 results were reported, with revenue up 7.8% and full-year guidance raised.

Merit Medical reported better-than-expected financial results in Q3 2024, with revenue increasing by 7.8% to $339.8 million. The company saw improvements in non-GAAP operating margin and non-GAAP EPS, and generated $120 million in free cash flow over the first nine months of 2024. Updated financial guidance for fiscal year 2024 reflects stronger-than-expected organic growth and profitability.

  • Reported revenue of $339.8 million, up 7.8%.
  • GAAP operating margin of 11.0%, compared to 11.1% in prior year period.
  • GAAP EPS $0.48, up 8.0%, and non-GAAP EPS $0.86, up 21.1%.
  • Completed the acquisition of certain assets from EndoGastric Solutions, Inc.

Headline financials

Total Revenue

$340M

Previous: $315M+7.8%
EPS

$0.48

Previous: $0.75-36.0%
GAAP Operating Margin

11.0%

Previous: 11.1%-0.9%
Non-GAAP Operating Margin

19.2%

Previous: 18.3%+4.9%
Capital Expenditures

-$31.7M

Previous: -$27.2M-16.6%
Free Cash Flow

-$3.22M

Previous: -$1.32M-144.8%
Net Income

$28.4M

Previous: $25.8M+10.1%
Operating Income

$37.3M

Previous: $35.1M+6.0%
Gross Profit

$158M

Previous: $142M+10.8%
Cash & Equivalents

$523M

Previous: $58.7M+791.6%
Total Assets

$2.38B

Previous: $1.81B+31.5%
R&D Expense

$20.5M

Previous: $19.6M+4.5%
Stock-Based Comp

$6.71M

Previous: $5.8M+15.8%

Revenue & EPS history

Merit Medical · Revenue · Quarterly

$340M

Q3 2024+7.8%vs Q3 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Merit Medical · $9.15M total across 1 segment · Q3 2023

  • Endoscopy
    $9.15M+11.2%

Forward guidance

Merit Medical updated its fiscal year 2024 financial guidance to reflect the stronger-than-expected organic growth and profitability results to-date. The updated guidance continues to assume the forecasted impacts from the acquisition of EndoGastric Solutions and the projected impacts from the acquisition of assets from Cook Medical.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-0.1%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+1.8%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+16.5%

Q3 2014

Best reaction

-31.4%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.2%-6.8%-2.8%
Q4 2025-3.8%-7.2%-16.6%
Q3 2025+5.1%+4.9%+4.3%
Q1 2025-0.1%-0.2%+0.7%
Q4 2024-1.5%+1.0%+1.9%
Q3 2024+2.9%+3.3%+8.3%
Q2 2024+4.0%+5.0%+13.4%
Q1 2024+2.1%+5.2%+7.8%
Q4 2023-5.3%-4.9%-5.9%
Q3 2023+7.7%+7.3%+12.9%
Q2 2023-9.6%-8.3%-16.4%
Q1 2023+4.7%+5.1%+4.3%
Q4 2022+2.8%+1.3%+3.7%
Q3 2022+7.0%+14.6%+19.6%
Q2 2022+6.0%+10.6%+10.0%
Q1 2022-3.7%-4.7%-5.2%
Q4 2021+8.4%+9.3%+5.0%
Q3 2021-1.8%-5.1%-3.5%
Q2 2021+7.6%+3.9%+10.1%
Q1 2021-0.2%+1.4%-5.3%
Q4 2020-1.8%-0.4%+1.9%
Q3 2020+5.2%+1.3%+11.7%
Q2 2020+4.3%-1.9%+11.6%
Q1 2020+9.0%+6.5%+21.4%
Q4 2019+0.4%-9.5%-17.0%
Q3 2019-31.4%-15.5%-7.0%
Q2 2019-24.7%-26.2%-37.2%
Q1 2019-1.9%-4.7%-9.4%
Q4 2018-4.3%-2.1%+1.6%
Q3 2018-4.1%-5.3%-3.5%
Q2 2018+2.8%-3.1%+3.3%
Q1 2018+2.8%+7.5%+18.7%
Q4 2017-2.1%-5.1%-3.3%
Q3 2017-9.7%-11.0%+4.6%
Q2 2017+4.8%+5.5%+4.6%
Q1 2017+8.2%+8.2%+11.6%
Q4 2016+5.9%+4.8%+0.0%
Q3 2016-5.0%-5.0%+5.2%
Q2 2016+6.1%+6.7%+6.5%
Q1 2016+2.5%
Q4 2015-2.8%
Q3 2015-27.3%
Q2 2015+10.7%
Q1 2015+9.5%
Q4 2014+7.7%
Q3 2014+16.5%
Q2 2014-14.4%
Q1 2014-5.4%
Q4 2013+1.2%
Q3 2013+15.4%
Q2 2013+7.6%
Q1 2013-13.9%
Q4 2012-14.7%
Q3 2012-2.8%
Q2 2012-0.5%
Q1 2011-0.7%
Q4 2011-0.7%
Q1 2012+1.1%
Q1 2010-1.6%
Q4 2009-1.6%
Q3 2010-1.1%
Q3 2011-1.1%
Q2 2011+1.6%
Q2 2010+1.6%
Q4 2010+1.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro